News

Brian C. Jensen, associate professor of medicine and pharmacology in the Department of Medicine’s Division of Cardiology, speaks about his research on kinase inhibitor cardiotoxicity.

A new study shows promise for intravascular lithotripsy (IVL)-assisted TMVR to treat a severely calcified mitral valve in a patient with severe stenosis and mitral regurgitation (MR).  

All patients undergoing procedures requiring anesthesia should be asked about cannabis use, according to guidelines released by the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine). The first...

The Society for Cardiovascular Angiography & Interventions (SCAI) announced four recipients of their Early Career Research Grants, a new initiative offered by SCAI to support the next generation of interventional cardiologists in advancing...

The legislation – which passed both the U.S. Senate and House of Representatives by unanimous vote this month – outlines efforts to take action based on research findings, including identifying and disseminating best practices for relevant...

The FLEX Vessel Prep™ System is VentureMed's AV and PAD product designed to create longitudinal micro-incisions that release circumferential lesion tension allowing lower balloon inflation pressures and potentially enhancing drug delivery...

“Our study aimed to determine whether the known protective effect of coffee also applies to individuals with different degrees of hypertension; and also examined the effects of green tea in the same population,” explained the study’s senior...

The team hypothesizes two main reasons for these findings: lower stress and faster sleep onset. Previous research has shown that faster onset of sleep can improve sleep quality and improved hypertension control.

“All of the disease characteristics we see because of these mutations were reversed with CRISPR-Cas9 therapy. It’s fair to say the success of this approach completely exceeded our expectations,” said Eric Olson, Ph.D.

Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial.